One Shot for Cholesterol? Lilly Thinks the Future Is Here

Lilly's Verve buyout could turn lifelong cholesterol drugs into a one-time genetic fix.

26 Jul 2025

Eli Lilly just dropped $1.3 billion on a bold idea: that heart disease might one day be treated with a single dose of gene editing instead of decades of pills and injections. The company closed its acquisition of Verve Therapeutics on July 25, marking one of the biggest bets yet on genetic medicine for common conditions.

At the center is VERVE-102, an experimental therapy that edits the PCSK9 gene in the liver. Shutting down this gene lowers LDL, the so-called bad cholesterol that fuels heart attacks and strokes. Early trial data show an average LDL drop of more than half, with some patients seeing far deeper cuts. Just as crucial, researchers haven't flagged serious safety problems.

That kind of durability could upend a treatment landscape now dominated by drugs from Amgen, Regeneron, and Novartis, all of which require repeat dosing. A one-and-done approach would lighten the burden on patients and could shift the economics of cardiovascular care. Analysts say Lilly is aiming not just to compete but to rewrite the playbook.

The deal itself reflects that ambition. Lilly is paying $1 billion upfront, with another $300 million tied to whether VERVE-102 clears key Phase 3 hurdles. The structure signals confidence but also hedges against risk. Investors responded quickly, sending Verve shares higher and framing the buyout as a milestone moment for gene editing's move into mainstream medicine.

Plenty of uncertainty lingers. Regulators will want long-term safety data. Insurers may balk at high upfront costs. And scaling a genetic therapy for millions is uncharted territory. Still, the global toll of cardiovascular disease leaves little doubt about the demand for breakthroughs.

If Lilly can deliver, the acquisition could mark a turning point: the moment when permanent genetic fixes began to edge out a lifetime of chronic treatment. For now, the company has planted a flag in the future of cholesterol care, and the race is officially on.